John Zajecka

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. ncbi request reprint High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial
    Philip T Ninan
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road, Atlanta, GA 30329, USA
    J Clin Psychiatry 67:15-22. 2006
  2. ncbi request reprint Augmentation strategies to increase antidepressant tolerability
    John M Zajecka
    Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychiatry 68:23-7. 2007
  3. ncbi request reprint A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder
    John M Zajecka
    Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612 3824, USA
    J Clin Psychiatry 63:1148-55. 2002
  4. ncbi request reprint SNRIs in the management of acute major depressive disorder
    John M Zajecka
    Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychiatry 65:11-8. 2004
  5. doi request reprint Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study
    P E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, and Linder Center of HOPE, Mason, Ohio 45267, USA
    J Affect Disord 112:36-49. 2009
  6. ncbi request reprint Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Biol Psychiatry 58:347-54. 2005
  7. ncbi request reprint Antidepressant dosing and switching guidelines: focus on nefazodone
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 63:42-7. 2002
  8. doi request reprint Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial
    John Zajecka
    Treatment Research Center, Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychopharmacol 30:135-44. 2010
  9. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
  10. ncbi request reprint Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724 5002, USA
    Biol Psychiatry 54:806-17. 2003

Detail Information

Publications20

  1. ncbi request reprint High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial
    Philip T Ninan
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road, Atlanta, GA 30329, USA
    J Clin Psychiatry 67:15-22. 2006
    ..To evaluate the efficacy and safety of high-dose sertraline for patients with obsessive-compulsive disorder (OCD) who failed to respond to standard sertraline acute treatment...
  2. ncbi request reprint Augmentation strategies to increase antidepressant tolerability
    John M Zajecka
    Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychiatry 68:23-7. 2007
    ..Pharmacologic and nonpharmacologic strategies can be used to improve the tolerability of antidepressants, resulting in a greater probability of achieving and sustaining remission...
  3. ncbi request reprint A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder
    John M Zajecka
    Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612 3824, USA
    J Clin Psychiatry 63:1148-55. 2002
    ..This study compared the efficacy, safety, and tolerability of divalproex and olanzapine in the treatment of acute mania associated with bipolar disorder...
  4. ncbi request reprint SNRIs in the management of acute major depressive disorder
    John M Zajecka
    Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychiatry 65:11-8. 2004
    ..Given the available evidence and the importance of remission, the pendulum has swung to consider using agents with dual reuptake inhibition (e.g., SNRIs) as standard and initial treatment for depression...
  5. doi request reprint Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study
    P E Keck
    Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, and Linder Center of HOPE, Mason, Ohio 45267, USA
    J Affect Disord 112:36-49. 2009
    ..To evaluate the efficacy and safety of aripiprazole as acute and maintenance of effect monotherapy for acute bipolar mania...
  6. ncbi request reprint Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Biol Psychiatry 58:347-54. 2005
    ..Vagus nerve stimulation (VNS) alters both concentrations of neurotransmitters or their metabolites and functional activity of central nervous system regions dysregulated in mood disorders. An open trial has suggested efficacy...
  7. ncbi request reprint Antidepressant dosing and switching guidelines: focus on nefazodone
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 63:42-7. 2002
    ..In clinical trials, the efficacy of nefazodone was most clearly established at doses between 300 and 600 mg/day. At this dose range, discontinuations because of adverse events are low...
  8. doi request reprint Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial
    John Zajecka
    Treatment Research Center, Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychopharmacol 30:135-44. 2010
    ..The results showed significant antidepressant efficacy of agomelatine 50 mg/d, including a positive effect on sleep compared with placebo in outpatients with moderate to severe major depressive disorder...
  9. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
    ..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression...
  10. ncbi request reprint Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724 5002, USA
    Biol Psychiatry 54:806-17. 2003
    ..This randomized, placebo-controlled study of the efficacy and safety of nefazodone in preventing recurrence was conducted for patients with chronic MDD...
  11. ncbi request reprint Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
    J Clin Psychiatry 63:434-41. 2002
    ....
  12. ncbi request reprint Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
    ..This study compares the effects of antidepressant medication, psychotherapy, and combined treatment on sexual interest/satisfaction and function in patients with chronic major depression...
  13. ncbi request reprint Treating depression to remission
    John M Zajecka
    Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychiatry 64:7-12. 2003
    ....
  14. ncbi request reprint A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder
    Richard C Shelton
    Department of Psychiatry, Vanderbilt University Medical Center, Nashville, Tenn, USA
    J Clin Psychiatry 67:1674-81. 2006
    ..The objective of the current multisite study was to compare relatively higher doses of sertraline (i.e., 150 mg/day) and venlafaxine extended release (XR) (225 mg/day) in outpatients with major depressive disorder...
  15. ncbi request reprint Calming the bipolar storm: treating acute mania and mixed episodes in patients with bipolar disorder
    John M Zajecka
    Treatment Research Center, Department of Psychiatry, Rush University Medical Center, Chicago, Ill, USA
    CNS Spectr 11:1-11; discussion 12-3; quiz 14-6. 2006
    ..The aim is to educate clinicians about ways to diagnose and treat the mood state aggressively and safely, especially in light of the many new treatment options available...
  16. ncbi request reprint Preventing recurrent depression: long-term treatment for major depressive disorder
    Pierre Blier
    Department of Psychiatry, Institute of Mental Health Research, University of Ottawa, Canada
    J Clin Psychiatry 68:e06. 2007
    ..Maintenance therapy considerations for clinicians include assessing treatment guidelines, addressing nonadherent patients, and measuring medication treatment response...
  17. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
    Martin B Keller
    Brown University, Providence, Rhode Island 02906, USA
    Biol Psychiatry 62:1371-9. 2007
    ..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment...
  18. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
    J Clin Psychiatry 68:1246-56. 2007
    ..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression...
  19. ncbi request reprint Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes
    Dennis A Revicki
    Center for Outcomes Research, MEDTAP International, Bethesda, MD 20814, USA
    J Clin Psychiatry 64:288-94. 2003
    ..This study compares the clinical, health-related quality of life (HRQL), and economic outcomes of divalproex and olanzapine in the treatment of acute mania associated with bipolar disorder...
  20. ncbi request reprint Oral divalproex sodium loading for adolescent outpatients with acute mania/hypomania: a report of 2 cases
    John M Zajecka
    J Clin Psychiatry 69:1016-8. 2008

Research Grants6

  1. Prevention of Recurrence in Depression with Drugs and Cognitive Therapy
    John Zajecka; Fiscal Year: 2007
    ....
  2. Prevention of Recurrence in Depression with Drugs and Cognitive Therapy
    John Zajecka; Fiscal Year: 2009
    ....
  3. 2/2-Prevention of Relapse & Recurrence of Bipolar Depression
    John Zajecka; Fiscal Year: 2009
    ..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..
  4. Prevention of Recurrence in Depression with Drugs and Cognitive Therapy
    John M Zajecka; Fiscal Year: 2010
    ....
  5. 2/2-Prevention of Relapse & Recurrence of Bipolar Depression
    John M Zajecka; Fiscal Year: 2010
    ..Results from this study may also inform new research hypotheses for future trials in BP I disorder. ..